Works matching IS 13419625 AND DT 2025 AND VI 30 AND IP 3

Results: 19
    1
    2
    3

    Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy for locally advanced maxillary sinus cancer (JCOG1212): final analysis.

    Published in:
    International Journal of Clinical Oncology, 2025, v. 30, n. 3, p. 489, doi. 10.1007/s10147-025-02702-8
    By:
    • Shinomiya, Hirotaka;
    • Matsuura, Kazuto;
    • Onimaru, Rikiya;
    • Ohkoshi, Akira;
    • Saito, Yuki;
    • Tachibana, Hiroyuki;
    • Shiga, Kiyoto;
    • Ueda, Tsutomu;
    • Asada, Yukinori;
    • Uemura, Hirokazu;
    • Beppu, Takeshi;
    • Seto, Akira;
    • Yasumatsu, Ryuji;
    • Nakahira, Mitsuhiko;
    • Omura, Go;
    • Asakage, Takahiro;
    • Minami, Shujiro;
    • Fujii, Takashi;
    • Hirayama, Yuji;
    • Yoshida, Daisuke
    Publication type:
    Article
    4

    A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer.

    Published in:
    International Journal of Clinical Oncology, 2025, v. 30, n. 3, p. 514, doi. 10.1007/s10147-025-02701-9
    By:
    • Ando, Koji;
    • Satake, Hironaga;
    • Shimokawa, Mototsugu;
    • Yasui, Hisateru;
    • Negoro, Yuji;
    • Kinjo, Tatsuya;
    • Kizaki, Junya;
    • Baba, Kenji;
    • Orita, Hiroyuki;
    • Hirata, Keiji;
    • Sakamoto, Sanae;
    • Makiyama, Akitaka;
    • Saeki, Hiroshi;
    • Tsuji, Akihito;
    • Baba, Hideo;
    • Oki, Eiji
    Publication type:
    Article
    5
    6
    7

    Paclitaxel plus cetuximab versus nivolumab for patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.

    Published in:
    International Journal of Clinical Oncology, 2025, v. 30, n. 3, p. 480, doi. 10.1007/s10147-025-02698-1
    By:
    • Kodama, Hiroyuki;
    • Kadowaki, Shigenori;
    • Ishizuka, Yasunobu;
    • Wakabayashi, Munehiro;
    • Sakakida, Tomoki;
    • Honda, Kazunori;
    • Masuishi, Toshiki;
    • Narita, Yukiya;
    • Taniguchi, Hiroya;
    • Ando, Masashi;
    • Kishikawa, Toshihiro;
    • Terada, Hoshino;
    • Beppu, Shintaro;
    • Nishikawa, Daisuke;
    • Suzuki, Hidenori;
    • Hanai, Nobuhiro;
    • Muro, Kei
    Publication type:
    Article
    8
    9

    Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.

    Published in:
    International Journal of Clinical Oncology, 2025, v. 30, n. 3, p. 497, doi. 10.1007/s10147-025-02696-3
    By:
    • Hotta, Katsuyuki;
    • Saeki, Sho;
    • Sakata, Shinya;
    • Yamaguchi, Masafumi;
    • Harada, Daijiro;
    • Bessho, Akihiro;
    • Tanaka, Kentaro;
    • Inoue, Koji;
    • Gemba, Kenichi;
    • Kubo, Toshio;
    • Sato, Akiko;
    • Ichihara, Eiki;
    • Watanabe, Hiromi;
    • Kishimoto, Junji;
    • Shioyama, Yoshiyuki;
    • Katsui, Kuniaki;
    • Sugio, Kenji;
    • Kiura, Katsuyuki
    Publication type:
    Article
    10

    The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma.

    Published in:
    International Journal of Clinical Oncology, 2025, v. 30, n. 3, p. 593, doi. 10.1007/s10147-025-02691-8
    By:
    • Nagata, Hiroaki;
    • Tsukamoto, Taku;
    • Kobayashi, Tsutomu;
    • Takahashi, Ryoichi;
    • Okano, Akira;
    • Uchiyama, Hitoji;
    • Kawata, Eri;
    • Uoshima, Nobuhiko;
    • Kaneko, Hiroto;
    • Fuchida, Shin-ichi;
    • Nishiyama, Daichi;
    • Nakao, Mitsushige;
    • Fujino, Takahiro;
    • Mizutani, Shinsuke;
    • Shimura, Yuji;
    • Kuroda, Junya
    Publication type:
    Article
    11
    12
    13

    Prognostic significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio in uterine carcinosarcoma: Systematic inflammatory response in ovarian clear cell carcinoma.

    Published in:
    International Journal of Clinical Oncology, 2025, v. 30, n. 3, p. 570, doi. 10.1007/s10147-024-02687-w
    By:
    • Sakurai, Azusa;
    • Yamaguchi, Ken;
    • Ishida, Kentaro;
    • Horikawa, Naoki;
    • Kawai, Eri;
    • Kotani, Yasushi;
    • Yoshida, Takaaki;
    • Kishimoto, Naoya;
    • Tatsumi, Keiji;
    • Okudate, Minami;
    • Iemura, Yoko;
    • Taga, Yukiko;
    • Aki, Megumi;
    • Ando, Yukiko;
    • Yanai, Akihiro;
    • Yamanoi, Koji;
    • Taki, Mana;
    • Murakami, Ryusuke;
    • Hamanishi, Junzo;
    • Mandai, Masaki
    Publication type:
    Article
    14
    15

    Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.

    Published in:
    International Journal of Clinical Oncology, 2025, v. 30, n. 3, p. 551, doi. 10.1007/s10147-024-02681-2
    By:
    • Tanegashima, Tokiyoshi;
    • Shiota, Masaki;
    • Terada, Naoki;
    • Saito, Toshihiro;
    • Yokomizo, Akira;
    • Kohei, Naoki;
    • Goto, Takayuki;
    • Kawamura, Sadafumi;
    • Hashimoto, Yasuhiro;
    • Takahashi, Atsushi;
    • Kimura, Takahiro;
    • Tabata, Ken-ichi;
    • Tomida, Ryotaro;
    • Hashimoto, Kohei;
    • Sakurai, Toshihiko;
    • Shimazui, Toru;
    • Sakamoto, Shinichi;
    • Kamiyama, Manabu;
    • Tanaka, Nobumichi;
    • Mitsuzuka, Koji
    Publication type:
    Article
    16
    17

    Comparison of the efficacy of enfortumab vedotin and paclitaxel plus carboplatin in patients with metastatic urothelial carcinoma.

    Published in:
    International Journal of Clinical Oncology, 2025, v. 30, n. 3, p. 524, doi. 10.1007/s10147-024-02678-x
    By:
    • Nakagawa, Ryunosuke;
    • Izumi, Kouji;
    • Toriumi, Ren;
    • Aoyama, Shuhei;
    • Kano, Hiroshi;
    • Makino, Tomoyuki;
    • Naito, Renato;
    • Kadomoto, Suguru;
    • Iwamoto, Hiroaki;
    • Yaegashi, Hiroshi;
    • Kawaguchi, Shohei;
    • Nohara, Takahiro;
    • Shigehara, Kazuyoshi;
    • Mizokami, Atsushi
    Publication type:
    Article
    18

    Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors.

    Published in:
    International Journal of Clinical Oncology, 2025, v. 30, n. 3, p. 539, doi. 10.1007/s10147-024-02676-z
    By:
    • Yamada, Yasutaka;
    • Sato, Kodai;
    • Sakamoto, Shinichi;
    • Tsujino, Takuya;
    • Saito, Sinpei;
    • Nishimura, Kazuki;
    • Fukushima, Tatsuo;
    • Nakamura, Ko;
    • Yoshikawa, Yuki;
    • Matsunaga, Tomohisa;
    • Maenosono, Ryoichi;
    • Kanesaka, Manato;
    • Arai, Takayuki;
    • Sazuka, Tomokazu;
    • Imamura, Yusuke;
    • Komura, Kazumasa;
    • Mikami, Kazuo;
    • Nakamura, Kazuyoshi;
    • Fukasawa, Satoshi;
    • Chiba, Kazuto
    Publication type:
    Article
    19

    Immunotherapy for endometrial cancer.

    Published in:
    International Journal of Clinical Oncology, 2025, v. 30, n. 3, p. 449, doi. 10.1007/s10147-024-02568-2
    By:
    • Wada, Michiko;
    • Yamagami, Wataru
    Publication type:
    Article